Inventor · disambiguated record
Holger Wesche
Also filed as: WESCHE HOLGER
26 granted patents·22 pending applications·192 citations·filing 2000–2024
96Inventor score
Files withHARPOON THERAPEUTICS INC38AMGEN RES MUNICH GMBH3AMGEN INC2MAVERICK THERAPEUTICS INC1TAKEDA PHARMACEUTICALS CO1
Top patents by PatentIndex Score
48 records- 0198US9708412B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2016·Granted Jul 18, 2017·66 cites·12 claims
- 0297US11180563B2FLT3 binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2021·Granted Nov 23, 2021·10 cites·27 claims
- 0396US10543271B2Mesothelin binding proteinsHARPOON THERAPEUTICS INC·Filed 2018·Granted Jan 28, 2020·13 cites·18 claims
- 0495US11085021B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Aug 10, 2021·3 cites·27 claims
- 0595US10849973B2Prostate specific membrane antigen binding proteinHARPOON THERAPEUTICS INC·Filed 2017·Granted Dec 1, 2020·10 cites·8 claims
- 0695US10844134B2PSMA targeting trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2017·Granted Nov 24, 2020·12 cites·11 claims
- 0795US10815311B2DLL3 binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2019·Granted Oct 27, 2020·14 cites·16 claims
- 0895US10730954B2MSLN targeting trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·14 cites·2 claims
- 0994US11136403B2Trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2018·Granted Oct 5, 2021·11 cites·13 claims
- 1094US10927180B2B cell maturation antigen binding proteinsHARPOON THERAPEUTICS INC·Filed 2018·Granted Feb 23, 2021·8 cites·18 claims
- 1192US12128102B2Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Oct 29, 2024·1 cites·15 claims
- 1292US10954311B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2017·Granted Mar 23, 2021·9 cites·21 claims
- 1387US10059766B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 28, 2018·9 cites·17 claims
- 1485US2025197526A1Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1579US11498964B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2018·Granted Nov 15, 2022·1 cites·17 claims
- 1679US2024327534A1B cell maturation antigen binding proteinsHARPOON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1778US12441796B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2022·Granted Oct 14, 2025·0 cites·17 claims
- 1878US2024141072A1Dll3 binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1976US2024100157A1Mesothelin binding proteinsHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2075US12084518B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2021·Granted Sep 10, 2024·0 cites·21 claims
- 2171US11976125B2B cell maturation antigen binding proteinsHARPOON THERAPEUTICS INC·Filed 2021·Granted May 7, 2024·0 cites·20 claims
- 2270US12371504B2Trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2021·Granted Jul 29, 2025·0 cites·25 claims
- 2369US11607453B2Mesothelin binding proteinsHARPOON THERAPEUTICS INC·Filed 2020·Granted Mar 21, 2023·0 cites·19 claims
- 2467US11807692B2DLL3 binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·0 cites·20 claims
- 2567US6818419B2IRAK-4: compositions and methods of useTULARIK INC·Filed 2001·Granted Nov 16, 2004·4 cites·11 claims
- 2667US2024218063A1Dll3 targeting trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2765US7235635B2IRAK-4: compositions and methods of useAMGEN INC·Filed 2004·Granted Jun 26, 2007·3 cites·3 claims
- 2864US2024254250A1Bcma targeting trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2964US2022098311A1Flt3 binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3062US2024084035A1Combination therapy with immune cell engaging proteins and immunomodulatorsHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3162US2020071405A1Antibody constructs for cdh19 and cd3AMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 3261US2021100902A1Prostate specific membrane antigen binding proteinHARPOON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3359US2021095047A1PSMA Targeting Trispecific Proteins and Methods of UseHARPOON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3459US2024336909A1Conditional activation of immunoglobulin moleculesHARPOON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3556US2024216518A1Extended-release immune cell engaging proteins and methods of treatmentHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3655US6822138B1NIK-knockout miceUNIV ST LOUIS·Filed 2000·Granted Nov 23, 2004·4 cites·7 claims
- 3751US2020270362A1Msln targeting trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3850US12195544B2EGFR binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2025·0 cites·29 claims
- 3949US2024228656A1Epcam targeting trispecific protein for treatment of cancerHARPOON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4047US11535668B2Inducible monovalent antigen binding proteinHARPOON THERAPEUTICS INC·Filed 2018·Granted Dec 27, 2022·0 cites·20 claims
- 4147US2022054544A1Conditionally active receptorsHARPOON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4243US12415860B2Binding moiety for conditional activation of immunoglobulin moleculesHARPOON THERAPEUTICS INC·Filed 2019·Granted Sep 16, 2025·0 cites·20 claims
- 4343US2021269530A1Conditionally activated binding protein comprising a sterically occluded target binding domainHARPOON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4443US2021284728A1Dual binding moietyHARPOON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4543US2019225702A1Innate immune cell trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4643US2020115461A1Compositions and methods for adoptive cell therapiesHARPOON THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4742US2021355219A1Conditionally activated target-binding moleculesHARPOON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4841US2018134789A1Inducible binding proteins and methods of useMAVERICK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Holger Wesche files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →